| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 20.589 | 27.446 | 26.728 | 26.136 | 26.217 | 27.482 | 28.524 |
| Total Income - EUR | - | - | - | 20.589 | 27.446 | 26.728 | 26.136 | 26.217 | 27.482 | 28.524 |
| Total Expenses - EUR | - | - | - | 469 | 780 | 668 | 886 | 735 | 8.474 | 9.537 |
| Gross Profit/Loss - EUR | - | - | - | 20.120 | 26.665 | 26.060 | 25.250 | 25.481 | 19.008 | 18.988 |
| Net Profit/Loss - EUR | - | - | - | 19.502 | 25.922 | 25.428 | 24.657 | 24.839 | 18.738 | 18.149 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Hema & Onco San S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | 20.115 | 27.068 | 27.407 | 49.772 | 25.124 | 20.339 | 20.894 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 19.106 | 25.560 | 25.497 | 48.541 | 24.527 | 15.743 | 15.831 |
| Cash | - | - | - | 1.009 | 1.508 | 1.910 | 1.231 | 597 | 4.596 | 5.063 |
| Shareholders Funds | - | - | - | 19.545 | 25.973 | 25.478 | 49.569 | 24.888 | 18.787 | 18.197 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 570 | 1.095 | 1.929 | 203 | 236 | 1.552 | 2.696 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Hema & Onco San S.r.l.